|Dr. Norbert W. Bischofberger||Pres, CEO & Director||280k||N/A||1956|
|Mr. Jorge F. DiMartino M.D., Ph.D.||Chief Medical Officer & Exec. VP of Clinical Devel.||398.27k||N/A||1963|
|Mr. Joshua A. Kazam||Co-Founder & Director||N/A||N/A||1977|
|Dr. Yasir B. Al-Wakeel||CFO & Head of Corp. Devel.||N/A||N/A||1982|
|Ms. Barbara A. Kosacz||COO & Gen. Counsel||N/A||N/A||1959|
|Dr. Christopher Dinsmore||Chief Scientific Officer||N/A||N/A||1967|
|Stephanie Yao||Exec. Director of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Dr. Pasit Phiasivongsa Ph.D.||Sr. VP of Pharmaceutical Devel.||N/A||N/A||N/A|
|Mr. Charles Lin Ph.D.||Sr. VP of Biology||N/A||N/A||N/A|
|Mr. David M. Tanen J.D.||Sec. & Director||N/A||N/A||1971|
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.
Kronos Bio, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.